Regulatory Compliance and Approval Risks: Caris operates in a highly regulated environment, and its diagnostic tests and services are subject to stringent oversight by agencies like the FDA and CLIA. Failure to obtain necessary regulatory approvals, maintain compliance with evolving regulations, or adequately respond to regulatory inquiries could delay market entry for new products or lead to restrictions on existing ones, impacting revenue and operations.

Reimbursement Challenges: Securing adequate reimbursement from government and commercial payers for its precision medicine tests is critical for Caris's financial viability. Uncertainty or reductions in reimbursement rates, changes in coverage policies, or difficulties in demonstrating clinical utility to payers could significantly limit market access and profitability, despite the scientific value of its offerings.

Intense Competitive Landscape: The precision oncology and genomic profiling market is highly competitive, with established players and new entrants offering similar or competing technologies. Caris faces competition from companies developing comprehensive genomic profiling, liquid biopsy, and AI-driven diagnostic solutions. Failure to differentiate its offerings, innovate rapidly, or effectively market its services could lead to loss of market share and pricing pressure.